Mostrar el registro sencillo del ítem

dc.contributor.authorSoriano, Vicente (1)
dc.contributor.authorAguilera, Antonio
dc.contributor.authorGonzález, Rocío
dc.contributor.authorGómez-Gallego, Felix (1)
dc.contributor.authorBarea, Luisa
dc.contributor.authorTreviño, Mercedes
dc.contributor.authorCorral, Octavio Jorge (1)
dc.date2019-11
dc.date.accessioned2020-04-22T06:56:23Z
dc.date.available2020-04-22T06:56:23Z
dc.identifier.issn1473-5687
dc.identifier.urihttps://reunir.unir.net/handle/123456789/9989
dc.description.abstractIntroduction Occult hepatitis B virus (HBV) infection, so-called occult B infection (OBI), is defined by the recognition of HBV-DNA in the absence of serum hepatitis B surface antigen (HBsAg). The HBV-DNA genome in OBI is fully replication competent and produced in the liver, characteristically with low-level HBV-DNA fluctuations in the bloodstream. The OBI status remains between chronic (HBsAg +) and resolved (anti-HBs +) phases in the natural history of HBV infection. Methods The clinical interest in OBI has increased because of its potential for overt HBV reactivation under immunosuppression as well as for HBV transmission, well established in recipients of blood transfusions and/or organ transplants. Results Given the shared transmission routes for HIV and HBV, earlier reports claimed that OBI was more frequent in AIDS patients. By contrast, the current scenario shows that OBI is negligible in the HIV population. One explanation is that HBV immunization and recall vaccination campaigns have been very active in this group. A second and most important reason points to the wide use of antiretroviral regimens that include anti-HBV active agents, that is, tenofovir, lamivudine, and/or emtricitabine. They are recommended either as treatment for all HIV carriers or as pre-exposure prophylaxis for uninfected individuals at risk. The consequences are that HBV reactivations associated with HIV-related immunodeficiency have become very rare. Furthermore, HBV suppression with these antivirals has markedly reduced the likelihood of transmission from OBI carriers and/or acquisition by uninfected exposed individuals. Conclusion Enthusiasm unabated, however, new tenofovir-sparing antiretroviral regimens are becoming popular and might account for a resurgence of OBI in the HIV setting.es_ES
dc.language.isoenges_ES
dc.publisherEuropean Journal of Gastroenterology & Hepatologyes_ES
dc.relation.ispartofseries;vol. 31, nº 11
dc.relation.urihttps://journals.lww.com/eurojgh/Abstract/2019/11000/Occult_hepatitis_B_and_HIV_infection.16.aspxes_ES
dc.rightsrestrictedAccesses_ES
dc.subjectantiretroviral drugses_ES
dc.subjecthepatitis Bes_ES
dc.subjectHIVes_ES
dc.subjectimmune deficiencyes_ES
dc.subjectliveres_ES
dc.subjectoccult B infectiones_ES
dc.subjectoccult hepatitis Bes_ES
dc.subjectpre-exposure prophylaxises_ES
dc.subjecttenofovires_ES
dc.subjectJCRes_ES
dc.subjectScopuses_ES
dc.titleOccult hepatitis B and HIV infectiones_ES
dc.typeArticulo Revista Indexadaes_ES
reunir.tag~ARIes_ES
dc.identifier.doihttps://dx.doi.org/10.1097/MEG.0000000000001417


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem